Cliff Asness's JAZZ Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 877,267 shares of Jazz Pharmaceuticals plc (JAZZ) worth $149.14 M, representing 0.08% of the portfolio. First purchased in 2014-Q4, this long-term strategic position has been held for 44 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in JAZZ, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2019, adding 633,022 shares. Largest reduction occurred in Q3 2020, reducing 630,550 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Jazz Pharmaceuticals plc (JAZZ) Holding Value Over Time
Track share changes against reported price movement
Quarterly Jazz Pharmaceuticals plc (JAZZ) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +178,326 | Add 25.51% | 877,267 | $170.00 |
| Q3 2025 | -95,829 | Reduce 12.06% | 698,941 | $130.15 |
| Q2 2025 | +304,463 | Add 62.10% | 794,770 | $106.12 |
| Q1 2025 | -43,375 | Reduce 8.13% | 490,307 | $122.00 |
| Q4 2024 | -19,883 | Reduce 3.59% | 533,682 | $123.15 |
| Q3 2024 | -65,535 | Reduce 10.59% | 553,565 | $110.86 |
| Q2 2024 | -125,546 | Reduce 16.86% | 619,100 | $106.73 |
| Q1 2024 | +440,363 | Add 144.72% | 744,646 | $120.42 |
| Q4 2023 | +125,172 | Add 69.89% | 304,283 | $123.00 |
| Q3 2023 | +51,871 | Add 40.77% | 179,111 | $129.44 |
| Q2 2023 | -25,218 | Reduce 16.54% | 127,240 | $123.97 |
| Q1 2023 | +41,241 | Add 37.08% | 152,458 | $144.84 |
| Q4 2022 | +79,010 | Add 245.32% | 111,217 | $158.08 |
| Q3 2022 | +32,207 | New Buy | 32,207 | $133.29 |
| Q1 2022 | -151,827 | Sold Out | 0 | $0.00 |
| Q4 2021 | -325,496 | Reduce 68.19% | 151,827 | $127.40 |
| Q3 2021 | -481,068 | Reduce 50.20% | 477,323 | $130.21 |
| Q2 2021 | -114,969 | Reduce 10.71% | 958,391 | $176.79 |
| Q1 2021 | +60,065 | Add 5.93% | 1.07 M | $164.37 |
| Q4 2020 | -290,936 | Reduce 22.31% | 1.01 M | $163.23 |
| Q3 2020 | -630,550 | Reduce 32.59% | 1.3 M | $141.38 |
| Q2 2020 | -419,046 | Reduce 17.80% | 1.93 M | $109.05 |
| Q1 2020 | +387,575 | Add 19.71% | 2.35 M | $99.74 |
| Q4 2019 | +633,022 | Add 47.48% | 1.97 M | $148.81 |
| Q3 2019 | +276,211 | Add 26.13% | 1.33 M | $127.12 |
| Q2 2019 | +337,396 | Add 46.89% | 1.06 M | $139.54 |
| Q1 2019 | +216,323 | Add 42.98% | 719,623 | $141.40 |
| Q4 2018 | +158,987 | Add 46.18% | 503,300 | $123.96 |
| Q3 2018 | +210,156 | Add 156.65% | 344,313 | $168.13 |
| Q2 2018 | +13,948 | Add 11.60% | 134,157 | $173.00 |
| Q1 2018 | +2,545 | Add 2.16% | 120,209 | $150.99 |
| Q4 2017 | +89,601 | Add 319.29% | 117,664 | $134.65 |
| Q3 2017 | -4,661 | Reduce 14.24% | 28,063 | $146.24 |
| Q2 2017 | -126,367 | Reduce 79.43% | 32,724 | $155.51 |
| Q1 2017 | -190,321 | Reduce 54.47% | 159,091 | $145.13 |
| Q4 2016 | +40,237 | Add 13.01% | 349,412 | $109.03 |
| Q3 2016 | +276,790 | Add 854.69% | 309,175 | $121.48 |
| Q2 2016 | +10,513 | Add 48.07% | 32,385 | $141.30 |
| Q1 2016 | -11,049 | Reduce 33.56% | 21,872 | $130.53 |
| Q4 2015 | +13,417 | Add 68.79% | 32,921 | $140.55 |
| Q3 2015 | +13,620 | Add 231.48% | 19,504 | $132.79 |
| Q2 2015 | -22 | Reduce 0.37% | 5,884 | $176.07 |
| Q1 2015 | -11,500 | Reduce 66.07% | 5,906 | $172.71 |
| Q4 2014 | +17,406 | New Buy | 17,406 | $163.74 |
Cliff Asness's Jazz Pharmaceuticals plc Investment FAQs
Cliff Asness first purchased Jazz Pharmaceuticals plc (JAZZ) in Q4 2014, acquiring 17,406 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Jazz Pharmaceuticals plc (JAZZ) for 44 quarters since Q4 2014.
Cliff Asness's largest addition to Jazz Pharmaceuticals plc (JAZZ) was in Q4 2019, adding 1,966,252 shares worth $292.6 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 877,267 shares of Jazz Pharmaceuticals plc (JAZZ), valued at approximately $149.14 M.
As of the Q4 2025 filing, Jazz Pharmaceuticals plc (JAZZ) represents approximately 0.08% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Jazz Pharmaceuticals plc (JAZZ) was 2,353,827 shares, as reported at the end of Q1 2020.